I

Immunic Therapeutics

83 employees

Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

Investor insights

Funding rounds participated in

$240M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2016

Funding rounds raised

Total raised

$240M

from 2 investors over 1 rounds

I

Immunic Therapeutics raised $240M on February 4, 2024

Investors: Biotechnology Value Fund and + 4 Other investors